×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MESO – mesoblast limited - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MESO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
08:42 am
meso
Stem Cell Therapy Market Expected To Reach 31.33 Billion, Growing at 11.20% CAGR By 2032 | Introspective Market Research [Yahoo! Finance]
Medium
Report
Stem Cell Therapy Market Expected To Reach 31.33 Billion, Growing at 11.20% CAGR By 2032 | Introspective Market Research [Yahoo! Finance]
11/7
11:11 pm
meso
ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth [Yahoo! Finance]
Low
Report
ASX Growth Companies With High Insider Ownership Seeing Up To 61% Earnings Growth [Yahoo! Finance]
10/30
07:16 pm
meso
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 [Yahoo! Finance]
Medium
Report
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024 [Yahoo! Finance]
10/30
07:11 pm
meso
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
Medium
Report
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
10/9
11:59 pm
meso
ASX Growth Companies With High Insider Ownership In October 2024 [Yahoo! Finance]
Low
Report
ASX Growth Companies With High Insider Ownership In October 2024 [Yahoo! Finance]
10/9
03:20 pm
meso
3 ASX Growth Companies With Insider Ownership Up To 37% [Yahoo! Finance]
Low
Report
3 ASX Growth Companies With Insider Ownership Up To 37% [Yahoo! Finance]
10/8
03:24 pm
meso
3 ASX Growth Stocks Insiders Own With Up To 45% Revenue Growth [Yahoo! Finance]
Low
Report
3 ASX Growth Stocks Insiders Own With Up To 45% Revenue Growth [Yahoo! Finance]
10/7
03:19 pm
meso
3 High Growth Tech Stocks in Australia to Watch [Yahoo! Finance]
Low
Report
3 High Growth Tech Stocks in Australia to Watch [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/24
83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast’s Cell Therapy Remestemcel-L
91.9%
4/6 FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19 27.0%
9/9 Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain 20.9%
4/8 MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY 11.4%
12/17 Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion 10.4%
4/29 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 8.7%
3/30 CLINICAL OUTCOMES OF MESOBLAST’S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS 8.5%
9/10 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.7%
6/24 Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices 6.8%
1/1 Mesoblast Submits Clinical Efficacy and Safety Data to FDA in Rolling Biologics License Application for Remestemcel-l [Yahoo! Finance News] 6.2%
4/6 FDA CLEARS INVESTIGATIONAL NEW DRUG APPLICATION FOR MESOBLAST TO USE REMESTEMCEL-L IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME CAUSED BY COVID-19 27.0%
9/9 Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain 20.9%
4/8 MESOBLAST PARTNERS WITH THE CARDIOTHORACIC SURGICAL TRIALS NETWORK ESTABLISHED BY THE U.S. NATIONAL INSTITUTES OF HEALTH’S NATIONAL HEART, LUNG AND BLOOD INSTITUTE TO CONDUCT RANDOMIZED CONTROLLED TRIAL OF REMESTEMCEL-L FOR PATIENTS WITH ACUTE RESPIRATORY 11.4%
12/17 Mesoblast’s Phase 3 Trial of Revascor in Advanced Chronic Heart Failure Surpasses the Number of Primary Endpoint Events for Trial Completion 10.4%
4/29 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 8.7%
3/30 CLINICAL OUTCOMES OF MESOBLAST’S CELL THERAPY IN END-STAGE ISCHEMIC HEART FAILURE PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY VIRTUAL SCIENTIFIC SESSIONS 8.5%
9/10 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 7.7%
6/24 Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices 6.8%
1/1 Mesoblast Submits Clinical Efficacy and Safety Data to FDA in Rolling Biologics License Application for Remestemcel-l [Yahoo! Finance News] 6.2%
TOP News Decliners
4/27
Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
-18.4%
6/26 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.9%
2/24 Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD -8.5%
9/18 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%
4/30 Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment -5.1%
5/30 Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 -5.0%
8/14 Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial -4.7%
4/10 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. -4.5%
4/1 FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEW -4.2%
10/19 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%
6/26 Mesoblast limited (NASDAQ: MESO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.9%
2/24 Consistent Outcomes Using Ryoncil™ as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD -8.5%
9/18 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%
4/30 Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment -5.1%
5/30 Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019 -5.0%
8/14 Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial -4.7%
4/10 Mesoblast limited (NASDAQ: MESO) had its "buy" rating re-affirmed by analysts at HC Wainwright. -4.5%
4/1 FDA ACCEPTS MESOBLAST’S BIOLOGICS LICENCE APPLICATION FOR RYONCIL™ AND AGREES TO PRIORITY REVIEW -4.2%
10/19 Mesoblast limited (NASDAQ: MESO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: